SPRO Stock Report - SmartPros Ltd

Spero Therapeutics Inc (SPRO) is a clinical-stage biopharmaceutical company that develops and commercializes novel treatments for multidrug-resistant bacterial infections and rare diseases. The company's lead product candidate, tebipenem HBr (SPR994), is a carbapenem-class antibiotic being developed for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis caused by gram-negative bacteria. SPRO is also developing SPR206, a next-generation IV-administered polymyxin product candidate, for the treatment of gram-negative infections, including carbapenem-resistant Enterobacteriaceae. The company's rare disease portfolio includes SPR720, an oral therapy for the treatment of rare, orphan diseases caused by underlying metabolic deficiencies. Spero Therapeutics is headquartered in Cambridge, Massachusetts, and as of September 2021, had a market capitalization of approximately $539.6 million.

Stock Sector: Diversified Services: Education & Training Services